NeuroScientific Biopharmaceuticals Ltd. announced the appointment of Dr. Jurgen Lindner as a consultant. Dr. Lindner has a PhD in neurosciences, and is a pharmaceutical professional with extensive experience in drug development and the manufacture of therapeutic products. He also has a strong track record of managing quality, compliance and regulatory affairs, and developing commercially viable solutions in a highly regulated environment.

Dr. Lindner's expertise will be instrumental as the Company prepares a new submission for ethics approval for EmtinBTM in the coming months. Additionally, after working as an Executive Director for NSB since the Company listed in 2018, Dr. Anton Uvarov is transitioning to a Non-executive Director in order to continue to support the Company and provide expert knowledge in his field. Dr. Uvarov's resignation from his Executive position is effective November 15, 2022 and for his services as a Non-executive Director.